Market-Moving News for June 18th
$ASNS
$ITCI
$LZB
Telecommunications Equipment
Telecommunications
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ASNS alert in real time by email
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 1/31/2025 | $119.00 → $132.00 | Buy → Hold | Canaccord Genuity | |
| 9/6/2024 | $68.00 → $92.00 | Neutral → Overweight | Piper Sandler | |
| 8/21/2024 | $43.00 | Buy → Neutral | Sidoti | |
| 1/3/2024 | $83.00 | Outperform | Robert W. Baird | |
| 12/11/2023 | $75.00 | Outperform | TD Cowen | |
| 4/20/2023 | $80.00 | Overweight | Morgan Stanley | |
| 8/25/2022 | Outperform → Mkt Perform | Raymond James | ||
| 8/22/2022 | $64.00 → $49.00 | Buy → Neutral | Goldman |
Canaccord Genuity downgraded Intra-Cellular Therapies from Buy to Hold and set a new price target of $132.00 from $119.00 previously
Piper Sandler upgraded Intra-Cellular Therapies from Neutral to Overweight and set a new price target of $92.00 from $68.00 previously
Sidoti downgraded La-Z-Boy from Buy to Neutral and set a new price target of $43.00
8-K - ACTELIS NETWORKS INC (0001141284) (Filer)
8-K/A - ACTELIS NETWORKS INC (0001141284) (Filer)
SCHEDULE 13G/A - Intra-Cellular Therapies, Inc. (0001567514) (Subject)
MONROE, Mich., Feb. 04, 2025 (GLOBE NEWSWIRE) -- La-Z-Boy Incorporated (NYSE:LZB) will report its Fiscal 2025 Third Quarter results for the period ended January 25, 2025 after the close of trading on the New York Stock Exchange on Tuesday, February 18, 2025, and will hold its quarterly investor conference call at 8:30 a.m. Eastern Time the following day, Wednesday, February 19, 2025. The conference call will be webcast live with corresponding slides at https://lazboy.gcs-web.com/. The dial-in phone number for the live conference call will be (888) 506-0062 for persons calling from within the U.S. or Canada, and the number for international callers will be (973) 528-0011. The participant a
Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults sNDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has potential to become a standard of care for most common depressive disorders CAPLYTA® adds to Johnson & Johnson's robust lineup of therapies with $5 billion+ potential in peak year salesi and further solidifies sales growth above analyst expectations now through the remainder of the decade Promising clinical-stage pipeline with best-in-disease potent
Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults sNDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has potential to become a standard of care for most common depressive disorders CAPLYTA® adds to Johnson & Johnson's robust lineup of therapies with $5 billion+ potential in peak year salesi and further solidifies sales growth above analyst expectations now through the remainder of the decade Promising clinical-stage pipeline with best-in-disease potential
3 - ACTELIS NETWORKS INC (0001141284) (Issuer)
4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)
FREMONT, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ:ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today announced the appointment of Julie Kunstler as an independent director to its Board of Directors, effective immediately. Kunstler brings over three decades of experience in the communications components, broadband access equipment sectors, and strategic corporate positioning, along with public company board experience. Kunstler currently serves on the board of Ethernity Networks Ltd., a company traded on the London Stock Exchange, and previously served on the
MONROE, Mich., Feb. 13, 2025 (GLOBE NEWSWIRE) -- La-Z-Boy Incorporated (NYSE:LZB), a global leader in the manufacture and retail of residential furniture, announced today that it has been recognized as one of America's Best Large Employers by Forbes for 2025. The list, produced in partnership with market research firm Statista, recognizes companies that excel across a broad spectrum of industries in six key dimensions: atmosphere and development, salary/wage, image, diversity, working conditions, and workplace environment. Forbes and Statista selected America's Best Employers in 2025 through an independent survey of over 217,000 U.S. employees working for companies with at least 1,000 emp
With a recently announced AI-powered cyber offering, impressive government contracts, on the backdrop of new tariffs that could bolster governmental engagements with American Companies, Actelis Networks' latest strategic moves seem to reinforce its position in the $154 Billion Dollar critical infrastructure protection market; Wall street analyst recently gave Actelis a $5 price target and buy recommendation Market News Alerts Reports: Actelis Networks* (NASDAQ:ASNS), a leader in cyber-hardened networking solutions, has appointed Dr. Niel Ransom to its Board of Directors. A veteran with nearly five decades in networking, cybersecurity, and deep-tech investment, Ransom brings critical exper
FREMONT, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ:ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today announced the appointment of Julie Kunstler as an independent director to its Board of Directors, effective immediately. Kunstler brings over three decades of experience in the communications components, broadband access equipment sectors, and strategic corporate positioning, along with public company board experience. Kunstler currently serves on the board of Ethernity Networks Ltd., a company traded on the London Stock Exchange, and previously served on the
With a recently announced AI-powered cyber offering, impressive government contracts, on the backdrop of new tariffs that could bolster governmental engagements with American Companies, Actelis Networks' latest strategic moves seem to reinforce its position in the $154 Billion Dollar critical infrastructure protection market; Wall street analyst recently gave Actelis a $5 price target and buy recommendation Market News Alerts Reports: Actelis Networks* (NASDAQ:ASNS), a leader in cyber-hardened networking solutions, has appointed Dr. Niel Ransom to its Board of Directors. A veteran with nearly five decades in networking, cybersecurity, and deep-tech investment, Ransom brings critical exper
FREMONT, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ:ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today announced the appointment of Dr. Niel Ransom, an industry veteran in networking, cybersecurity, and deep-tech investments, to its Board of Directors, effective immediately. Dr. Ransom is an industry luminary with nearly five decades of experience in networking and communications technology. He began his career at Bell Labs, contributing to industry-first innovations in applied research and product development. He later held pivotal leadership roles, including
SC 13G/A - ACTELIS NETWORKS INC (0001141284) (Subject)
SC 13G/A - Intra-Cellular Therapies, Inc. (0001567514) (Subject)
SC 13G - Intra-Cellular Therapies, Inc. (0001567514) (Subject)